Solid Tumor, Adult
Conditions
Brief summary
HTI-1066 is a novel ADC being developed for the treatment of cancers in patients with overexpression of c-Met. This 2-part, Phase 1 study evaluates the safety the tolerability of HTI-1066 in subjects with advanced solid tumors.
Detailed description
This is a 2-part dose escalation and dose expansion study. Dose escalation uses a modified 3+3 design and continues until a maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is identified. In part 2, subjects with selected tumor types will be enrolled at the MTD or RP2D.
Interventions
DRUGHTI-1066 dose level 1
Starting dose level
DRUGHTI-1066 dose level 2
2nd dose level
DRUGHTI-1066 dose level 3
3rd dose level
DRUGHTI-1066 dose level 4
4th dose level
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female ≥18 years of age 2. Subject must have an advanced solid tumor 3. ECOG Performance Status of 0 or 1 4. Life expectancy ≥12 weeks 5. Adequate laboratory parameters 6. Female subjects agree not to be pregnant or lactating from beginning of the study screening until 4 months after receiving the last treatment; Male and female subjects and their sexual partners are willing and able to employ a highly effective method of birth control/contraception. 7. Willing and able to comply with clinic visits and study-related procedures 8. Provide signed informed consent
Exclusion criteria
1. Hypersensitivity to HTI-1066 or sensitivity to humanized monoclonal antibody products 2. Any concurrent therapy for cancer, radiation, or surgery within 4 weeks, except for minor palliative intent (this is to be discussed with sponsor) 3. Any concurrent use of anti-infective, anti-fungal, or anti-viral agent (exceptions are to be approved by the sponsor) 4. Any other prohibited or restricted medication as described in the study protocol. 5. Investigational therapy administered \<5 half-lives before the first dose of HTI-1066 6. Any anticancer therapy administered \<5 half-lives before first dose of HTI-1066; any prior immune-oncology products administered within 4 weeks or 5 half-lives before the first dose of HTI-1066 as described above; or surgery or radiotherapy administered within 4 weeks before the first dose of HTI-1066. 7. Active CNS metastases. 8. Cardiac disease (NYHA classes II-IV) including myocardial infarction within 6 months before enrollment, or unstable angina, congestive heart failure, or cardiac arrhythmia requiring treatment. 9. History or presence of an abnormal ECG, ECHO, or MUGA that is clinically meaningful. 10. History of immunodeficiency including seropositivity for human immunodeficiency virus (HIV), or other acquired or congenital immune-deficient disease, or any active systemic viral infection requiring therapy (e.g., hepatitis B or C) 11. Any other medical, psychiatric, or social condition deemed by the investigator to be likely to interfere with a subject's rights, safety, welfare or ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results 12. Active infection or an unexplained fever \>38.5°C during Screening or on the first scheduled day of dosing. 13. Unresolved toxicities from previous anticancer therapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events | Up to 2 year | Number of participants with AEs and SAEs |
| Dose-limiting toxicity (DLT) | Up to 2 years | Number of participants with DLTs |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Anti-drug antibodies | Up to 2 year | — |
| AUC | Up to 1 year | Area under the curve |
| Progression-free survival (PFS) | Up to 2 years | — |
| Objective response rate | Up to 2 years | — |
| Cmax | Up to 1 year | Peak concentration at Tmax |
Countries
United States
Contacts
Primary ContactJunsheng Wang, MD, PhD
Backup ContactMatt Cromie, MSc
Outcome results
None listed